# Diabetes Research Hub — Monitor Report

**Run date:** 2026-08-01 (automated, unattended)
**Scope:** Review of latest script outputs in `Analysis/Results/`, snapshot comparison, and web breaking-news check. No existing files were modified (review-only run).

Confidence tags follow the Research Doctrine: **[Certain]** = read directly from files / independently verifiable, **[Likely]** = strong inference, **[Guessing]** = gap-filling.

---

## Headline (read this first)

**Two things changed this cycle — one bad, one worth acting on.**

1. **The baseline feeds are now frozen for a FOURTH consecutive cycle.** `clinical_trials_latest.json` and `pubmed_recent_latest.json` are both still stuck at **2026-07-17 — 15 days stale**, now past the doctrine's 14-day threshold by a full day. No new trial or PubMed snapshot has appeared since 07-17. This is a failed or disabled job, not a skip, and it has been diagnosed identically for four cycles running (07-28 → 08-01). **Escalate: this needs a human to look at the scheduler and the two script logs today.** [Certain]

2. **Genuinely new external signal: Lilly's retatrutide posted positive Phase 3 topline results on 2026-07-23 (TRIUMPH-2 and TRIUMPH-3) — inside the 7-day window, and retatrutide is on our therapy watchlist.** Our frozen PubMed feed shows only 4 retatrutide mentions and will not capture this until the feed recovers — a concrete example of what the stale pipeline is costing us. BLA submission to FDA is planned Q1 2027. [Certain — web-verified]

What is still running: the gap analysis re-ran (`literature_gap_report.md` regenerated **07-31**) and `agent_state.json` regenerated **07-31**, but the gap report's data range still ends **2026/07/17** — it is re-processing the same frozen corpus. Note the `agent_state.json.bak` series has **no 07-31 backup** (newest is 07-30), so even the state-backup job skipped a day. [Certain]

---

## File System Status

| File | Last modified | Age | Status |
|------|---------------|-----|--------|
| `clinical_trials_latest.json` | 2026-07-17 | 15 d | **STALE — past threshold** |
| `pubmed_recent_latest.json` | 2026-07-17 | 15 d | **STALE — past threshold** |
| `hub_monitor_report.md` | 2026-07-17 | 15 d | **Stale** |
| `literature_gap_data.json` | 2026-07-18 | 14 d | **Stale (at threshold)** |
| `literature_gap_report.md` | 2026-07-31 | 1 d | Fresh wrapper, **07-17 source data** |
| `agent_state.json` | 2026-07-31 | 1 d | Fresh |
| `agent_state.json.bak_*` | 2026-07-30 | 2 d | **No 07-31 backup** |

- Latest trial snapshot: `clinical_trials_snapshot_2026-07-17.json` — **no new snapshot in 15 days.** [Certain]
- Latest PubMed snapshot: `pubmed_recent_snapshot_2026-07-17.json` — same 15-day gap. [Certain]
- The 07-17 hub monitor flagged **827 result files older than 14 days**; that backlog keeps growing untouched. [Certain]

**Interpretation [Likely]:** `hub_monitor.py`, the gap runner, and (mostly) the agent-state backup still fire. `baseline_clinical_trials.py` and `baseline_pubmed_alerts.py` have produced nothing since 07-17 across four cycles. Root cause is almost certainly one of: expired ClinicalTrials.gov/PubMed API access, a network block, a disabled scheduler entry, or a changed hub-root path (the 07-17 monitor referenced `/sessions/intelligent-bold-bardeen/...`, a different session root than this run).

---

## Clinical Trial Changes

Source: `clinical_trials_latest.json` (generated 2026-07-17T02:05:53, ClinicalTrials.gov API v2). **858 trials** — T1D Cure & Cell Therapy 152, T1D Immunotherapy & Prevention 76, T2D Novel Therapies 147, Devices 236, Recently Completed w/ Results 321. [Certain — re-read from file this run]

**No snapshot diff exists since 07-17** — no new/changed/removed trials can be computed this cycle. Every entry below is the frozen 07-17 state, re-verified against the source JSON. [Certain]

### Phase 3 RECRUITING — key-organization trials to watch [Certain, re-verified via jq this run]

| NCT | Sponsor | Therapy / focus |
|-----|---------|-----------------|
| NCT06832410 | Vertex | Islet cell therapy (biologic) — Phase 3 |
| NCT04786262 | Vertex | VX-880 / zimislecel — Phase 3 |
| NCT07076199 | Novo Nordisk | Insulin icodec (weekly) |
| NCT07564414 | Novo Nordisk | CagriSema vs semaglutide |
| NCT07222332 | Eli Lilly | Baricitinib (preserve beta-cell function) |
| NCT07222137 | Eli Lilly | Baricitinib (delay Stage 3 T1D) |
| NCT07088068 | Sanofi | Teplizumab vs placebo |
| NCT06739122 | Eli Lilly | Dulaglutide |
| NCT07662044 / 07662109 / 07662213 / 07662135 | AstraZeneca | Elecoglipron (± dapagliflozin / semaglutide) |

Both Vertex zimislecel trials, both Lilly baricitinib trials, the Sanofi teplizumab trial, and the Novo CagriSema trial remain on the therapy watchlist. The four AstraZeneca elecoglipron Phase 3 trials are the newest key-org activity in the frozen data — now 15 days unrefreshed.

### Recently posted results (frozen list) [Certain, re-read from file]

The five watchlist-relevant results from 07-17 are unchanged (orforglipron NCT05086445 posted 07-16; tirzepatide vs dulaglutide NCT04255433 posted 07-08; icodec NCT06340854 posted 07-02; plus Bayer finerenone+empagliflozin and JHU social-risk CDS). Treat as reviewed unless the tracker still lists them open. **No new results can be detected while the feed is frozen.** [Certain]

---

## PubMed Highlights

Source: `pubmed_recent_latest.json` (generated 2026-07-17T02:06:39, 30-day lookback, **158 unique papers**, 16 domains). Frozen — identical corpus to the last three cycles. [Certain — re-read this run]

**Cross-domain papers (highest value, 12 total).** Top hits [Certain]:

- **[42459945]** *A framework for assessing algorithmic discrimination risks in training data: pediatric type 1 diabetes* — **AI/ML + Closed Loop AP + Health Equity** (3 domains). On our Tier-1 equity/epidemiology focus.
- **[42419792]** *Comparative effects of drugs for adults with overweight or obesity (systematic review)* — **orforglipron + retatrutide + CagriSema** (3 key therapies at once).
- [42437645] Variant-specific pharmacophoric shifts in GLP-1 receptor — GLP-1 pharmacogenomics.
- [42411999] T1D driven by residual recipient T cells after HSCT — stem-cell cure + immunotherapy.
- [42436543] Dynamics of healthcare inequalities in T2D — remission + health equity.
- [42458355] Socioeconomic gradients in hypertension/diabetes management — AI/ML + health equity.

**Key-therapy mentions (30-day counts, frozen):** dapagliflozin 52, orforglipron 10, CagriSema 6, retatrutide 4, teplizumab 4, icodec 3, baricitinib 2, **zimislecel 0**. [Certain]

The **zimislecel gap persists (0 hits despite two active Phase 3 trials)** — almost certainly a terminology miss; the alert is likely still keyed to "VX-880" and missing the "zimislecel" INN. Worth patching in `baseline_pubmed_alerts.py`. No volume-trend read is meaningful while the feed is frozen. [Certain]

---

## Gap Analysis Summary

Source: `literature_gap_report.md` (regenerated 2026-07-31, data range through 2026/07/17). Validation level **BRONZE** — single analytical source, requires expert confirmation. [Certain]

Top under-researched intersections (Gap Score 100 = zero joint publications):

1. **Treg / CAR-T × Neuropathy** — 100.0, 0 joint pubs
2. **Beta Cell Regen × Health Equity** — 100.0, 0
3. **Treg / CAR-T × Health Equity** — 100.0, 0
4. **Glucokinase × Health Equity** — 100.0, 0
5. **Gene Therapy × LADA** — 100.0, 0

(Also flagged: Drug Repurposing × Health Equity 100.0; Insulin Resistance × Islet Transplant 91.9.)

**Tier-1 alignment [Likely]:** The Doctrine's named Tier-1 areas (re-read from `RESEARCH_DOCTRINE.md` this run) are Multi-Omics Integration, Literature Synthesis/Gap Analysis, Clinical Trial Intelligence, Drug Repurposing, AI/ML Prediction, and Epidemiological Data Analysis. Beta Cell Regen is **not** itself a Tier-1 area. The intersection mapping to *two* genuine Tier-1 capabilities is **Drug Repurposing × Health Equity (100.0)** — repurposing (Tier-1 #4) plus epidemiology (Tier-1 #6), both areas where we have data access and computational tooling. Per doctrine, verify each is a real gap (combined-term PubMed search + Cochrane/PROSPERO check) before acting — **do not treat BRONZE findings as actionable.** Nothing here has changed since 07-31.

---

## Breaking News (web check, last 7 days)

**One genuinely new, significant event this cycle.** [Certain — web-verified]

- **Retatrutide — positive Phase 3 topline, TRIUMPH-2 and TRIUMPH-3 (announced 2026-07-23).** Lilly's GIP/GLP-1/glucagon triple agonist. TRIUMPH-2 (T2D + obesity, n≈1,152): all three doses (4/9/12 mg) delivered substantial weight loss and improved glycemic control at 80 weeks (up to ~20.8% weight loss; A1C −1.5% at 12 mg from 7.7% baseline). TRIUMPH-3 (severe obesity + established CVD): up to 22.6% average weight loss at 80 weeks. Lilly plans a **BLA submission to FDA in Q1 2027**. This is retatrutide's fourth/fifth positive Phase 3 readout. **Watchlist hit — flag for the tracker.** [Certain]

Standing context, not new this week:

- **Tzield (teplizumab, Sanofi) accelerated approval for Stage 3 T1D in children 8–17** — granted July 2026 on the Phase III PROTECT trial (n=328, C-peptide preservation). First disease-modifying therapy for newly-diagnosed Stage 3 pediatric T1D. Confirm the tracker records this; if not, it graduates teplizumab from watchlist to approved for this indication. [Certain]
- **Vertex zimislecel (VX-880):** still investigational; global regulatory submissions expected during 2026, realistic approval window 2027–2028. No confirmed new July/August-2026 filing found. [Likely]

---

## Recommended Actions

Ranked by urgency.

1. **[ESCALATE] Re-run the two stalled baseline scripts and read their logs — fourth consecutive stale cycle, now past the 14-day threshold:**
   - `python baseline_clinical_trials.py`
   - `python baseline_pubmed_alerts.py`
   Silent failure across 15 days points to expired API access, a network block, or a disabled scheduler entry — not a skip. This should not reach a fifth cycle.
2. **Diagnose the scheduler.** The gap and agent-state jobs run but the two baseline jobs do not, and agent-state itself skipped its 07-31 backup. If they share a runner, check for one disabled entry or a changed hub-root path (07-17 monitor referenced a different session root, `/sessions/intelligent-bold-bardeen/...`).
3. **Update the tracker with the retatrutide TRIUMPH-2/TRIUMPH-3 readout (2026-07-23)** and the planned Q1-2027 BLA. Cross-link to the retatrutide watchlist entry.
4. **Update the tracker with the Tzield Stage 3 pediatric approval** if not already logged.
5. **Patch the zimislecel query** in `baseline_pubmed_alerts.py` — 0 hits despite two active Phase 3 trials strongly suggests the alert is keyed to "VX-880" and missing the "zimislecel" INN.
6. **Do not action gap findings yet** — they are BRONZE. If pursuing the Health-Equity intersections (esp. Drug Repurposing × Health Equity), run the doctrine's verification (combined-term search + Cochrane/PROSPERO) to lift toward SILVER.
7. **Re-run `project1_literature_gap_analysis.py` only after the PubMed feed recovers** — the current gap report is built on 07-17 data, so re-running now reproduces today's result.

---

*Generated by the Diabetes Research Hub automated monitor — 2026-08-01. Review-only run; no source files modified. All trial/paper figures re-read directly from the source JSON this cycle; breaking-news items web-verified.*
